Could be. If so, it's at least an excuse for manipulators to take the pps down. However, Intuitive announced the Xi on 4/1 and pre-announced earnings 4/8. Novadaq started its slide 4/4, right between the two events. Cynically, I tend to believe in insider manipulation, so I am more likely to go with advanced selling on the pre-announcement. I don't think Firefly for Xi, in whatever form, will be delayed long.
Agreed that the Xi is Firefly ready, but the Si's Firefly unit sure doesn't look like it would fit on an Xi! My bet is that Novadaq has built them a new unit. What compensation arrangement for this may be specified under in the original agreement or maybe not. These questions will probably be answered shortly. I can't see Intuitive selling many Xi units without having the highly popular Firefly option available.
(posted on IV)
Not gained from any other source than by by looking at closeups of the following system photos and press releases, it looks like the da Vinci Xi is probably incompatible with the old Firefly endoscope. (1) The mounts are not the same. (2) The new Xi regular scope is much less bulky than the old Si endoscopes(regular and Firefly). An adapter for the old Si Firefly scope might be possible but weight, moment, size and clearance could be problematic. (3) The Si Firefly scope appears to use a dedicated arm whereas the Xi’s endoscope is moveable among the arms. (4) The Xi’s new regular endoscope has improved vision over the Si components.
My guess is that a new Firefly for the Xi is in existence and awaiting FDA approval. The question is whether it incorporates Novadaq's new technology, though I doubt if Intuitive would hitch their new machine to old technology. I'm not sure where this would leave us with regard to the particulars of the current Intuitive/Novadaq manufacturing agreement (we’re halfway through the ten year commitment) but an updated one would no doubt be more beneficial to Novadaq. An announcement of a new agreement MIGHT follow FDA approval.
Photos on company site in media images.
Links on IV-
Photo of Si without Firefly:
Photo Si with Firefly:
Photo of Xi without Firefly:
Following is a Novadaq patent application reference:
Quantification and analysis of angiography and perfusion.
US 20130345560 A1
Link provided on investor village.
I believe that Novadaq’s position as first mover in this intellectual property area will assure top tier status for their equipment for years to come. If they own perfusion quantification, they will own the field.
It's okay by me. Added another 5% to my portfolio today. Looking forward:
(1) The official Pillar II results have yet to be released. (2) Pressure will be on ISRG to upgrade Firefly visual definition and perfusion quantification. (3) No official announcement of the new Pinpoint has been made.
I, too, came here via the ISRG (2003) and Fish_disco route. The information Fish found and posted was vital. Though I was reluctant to buy NVDQ when it was only listed on the Toronto exchange, I bought it immediately when it hit the NASDAQ.
2015? Do you have a time machine, endo?
I'm not so sure they they can't present data. I could be wrong, but I think two journals have accepted and made the article available online and rendered it able to cited. Near Infra-red (NIR) laparoscopic assessment of the adequacy of blood perfusion of intestinal anastomosis. In colorectal disease or surgical endoscopy. A seach for NIR, Cahill, Ris should get you there.
The one I was referring to was investor village. The post I referenced was actually in the ISRG group. The NVDQ group is sporadic.
For some company discussions what IV lacks in volume, it makes for in post quality; for others ,especially small caps, posts can be few and far between. Spammers are not tolerated by admins like they are here. You don't find yourself wading through the same thread to find the latest message because the threads are collapsed or the post links you have already read show up in light blue instead of dark blue like they should. Reference article links are and quotations are encouraged rather than grounds for post rejection.
I think YH encourages convolution to get more clicks and thus more ad traffic.
A nod to streetsense on another board for finding a blurb about Firefly being used in robotic surgery to treat endometriosis at Kingwood Medical Center. It’s a good look-at-what-we-can-do-now/case-study piece.
I wasn't aware hospitals were informing the public about this application yet.
Pardon me if I'm wrong but I don't believe the paper you mention has much to do with Pillar II. Pillar II concerns cases of laparoscopic colon resection surgery utilizing PINPOINT and not robotic gall bladder surgery. Nonetheless, I'm still looking forward to SAGES!
Both Pinpoints are endoscopic devices. During at the RBC talk, at about the 12 minute mark, Arun described Pinpoint's capabilities both as an endoscope and a perfusion measuring system. He did mention that Pinpoint could replace other endoscopic systems in complex cases. This probably means Pinpoint is overkill for general use, but in cases where perfusion measurement is desired, an additional endoscope will not be required.
However, he made no reference to Pinpoint II until near the end of the talk and declined to reveal its features, saying these will discussed at SAGES when it will be officially unveiled.
Arun said that the average 40% growth rate was likely to result from less than 40% for partnered agreements (Intuitive/FIREFLY and Lifecell/SPY) and greater than 40% for self-vended products (LUNA and PINPOINT). Given the enhancements, better color image presentation, and perfusion quantification, my question is when will renegotiation of the Novadaq/Inutitive licensing and equipment sales agreement (ten year, signed 2009) occur? I don't think Intuitive will wait for expiration to get improved equipment.
I previously noted that during the RBC talk Arun mentioned that one selling point of PINPOINT was that it serves as a replacement endoscopic system and not just another added piece of equipment. Listening to the BarcIays webcast, it became clear that he really was referring to the new PINPOINT which will be unveiled at SAGES. Based on feedback gained in the field, beyond fluorescence and quantification of perfusion, the new PINPOINT will be aimed at replacing all the functions that surgeons are used to using with their old endoscopes: gas insufflation, data capture, and different sizes and shapes of scopes.
These greater capabilities should speed adoption in the OR and increase unit ASP.
The link wasn't included because I have no patience having a post dinged by yahoo because I included a link within. Any pointers on how you got yours past the YH nanny?
A small study - released in the past week - entitled Near-infrared (NIR) perfusion angiography in minimally invasive colorectal surgery, used Novadaq's PINPOINT in surgery on 30 consecutive patients. The mantra continues - no leaks. Go PILLAR.